Search Results

By Jo Cavallo  / Wednesday, March 12, 2014 2:04 PM

Patient With Bladder Cancer Shows Exceptional Response to Everolimus/Pazopanib Combination

A phase I study by Wagle et al of a combination of everolimus and pazopanib in patients with advanced solid tumors has identified a patient with bladder cancer who had a 14-month complete response. The patient had two concurrent mutations in mTOR, the target of everolimus (Afinitor), which may have ...